1SKF401E Stock Overview
Develops, manufactures, and sells generic medicinal products, primarily used in primary care sector in Slovak, Czech Republic, and internationally. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Zentiva, a.s. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €31.00 |
52 Week High | €32.20 |
52 Week Low | €30.00 |
Beta | 0 |
1 Month Change | -3.73% |
3 Month Change | -0.64% |
1 Year Change | 3.33% |
3 Year Change | 1.97% |
5 Year Change | -79.33% |
Change since IPO | -96.90% |
Recent News & Updates
Recent updates
Shareholder Returns
1SKF401E | SK Pharmaceuticals | SK Market | |
---|---|---|---|
7D | 0% | -7.3% | -0.1% |
1Y | 3.3% | -3.3% | 1.4% |
Return vs Industry: 1SKF401E exceeded the SK Pharmaceuticals industry which returned -3.3% over the past year.
Return vs Market: 1SKF401E exceeded the SK Market which returned 1.4% over the past year.
Price Volatility
1SKF401E volatility | |
---|---|
1SKF401E Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.4% |
Market Average Movement | 4.5% |
10% most volatile stocks in SK Market | 9.7% |
10% least volatile stocks in SK Market | 2.4% |
Stable Share Price: 1SKF401E's share price has been volatile over the past 3 months compared to the SK market.
Volatility Over Time: Insufficient data to determine 1SKF401E's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | n/a | n/a | www.zentiva.sk |
Zentiva, a.s. develops, manufactures, and sells generic medicinal products, primarily used in primary care sector in Slovak, Czech Republic, and internationally. The company offers prescription medicines. It also engages in the production and wholesaling of pharmaceuticals and chemical products.
Zentiva, a.s. Fundamentals Summary
1SKF401E fundamental statistics | |
---|---|
Market cap | €50.23m |
Earnings (TTM) | €2.29m |
Revenue (TTM) | €36.17m |
0.0x
P/E Ratio0.0x
P/S RatioIs 1SKF401E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1SKF401E income statement (TTM) | |
---|---|
Revenue | €36.17m |
Cost of Revenue | €13.50m |
Gross Profit | €22.67m |
Other Expenses | €20.38m |
Earnings | €2.29m |
Last Reported Earnings
Dec 31, 2018
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did 1SKF401E perform over the long term?
See historical performance and comparisonDividends
155.5%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 06:59 |
End of Day Share Price | 2024/12/11 00:00 |
Earnings | 2018/12/31 |
Annual Earnings | 2018/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zentiva, a.s. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|